Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dua...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.721286/full |
id |
doaj-e413afbaa85847fc89073dd1f5a18f3a |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudius Speer Claudius Speer Christian Morath Maximilian Töllner Mirabel Buylaert Daniel Göth Christian Nusshag Florian Kälble Matthias Schaier Julia Grenz Martin Kreysing Paula Reichel Asa Hidmark Gerald Ponath Paul Schnitzler Martin Zeier Caner Süsal Katrin Klein Louise Benning |
spellingShingle |
Claudius Speer Claudius Speer Christian Morath Maximilian Töllner Mirabel Buylaert Daniel Göth Christian Nusshag Florian Kälble Matthias Schaier Julia Grenz Martin Kreysing Paula Reichel Asa Hidmark Gerald Ponath Paul Schnitzler Martin Zeier Caner Süsal Katrin Klein Louise Benning Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 Frontiers in Medicine SARS-CoV-2 COVID-19 hemodialysis immune response vaccination |
author_facet |
Claudius Speer Claudius Speer Christian Morath Maximilian Töllner Mirabel Buylaert Daniel Göth Christian Nusshag Florian Kälble Matthias Schaier Julia Grenz Martin Kreysing Paula Reichel Asa Hidmark Gerald Ponath Paul Schnitzler Martin Zeier Caner Süsal Katrin Klein Louise Benning |
author_sort |
Claudius Speer |
title |
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_short |
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_full |
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_fullStr |
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_full_unstemmed |
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2 |
title_sort |
humoral responses to single-dose bnt162b2 mrna vaccination in dialysis patients previously infected with sars-cov-2 |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Medicine |
issn |
2296-858X |
publishDate |
2021-08-01 |
description |
Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both P < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity. |
topic |
SARS-CoV-2 COVID-19 hemodialysis immune response vaccination |
url |
https://www.frontiersin.org/articles/10.3389/fmed.2021.721286/full |
work_keys_str_mv |
AT claudiusspeer humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT claudiusspeer humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT christianmorath humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT maximiliantollner humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT mirabelbuylaert humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT danielgoth humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT christiannusshag humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT floriankalble humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT matthiasschaier humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT juliagrenz humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT martinkreysing humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT paulareichel humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT asahidmark humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT geraldponath humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT paulschnitzler humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT martinzeier humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT canersusal humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT katrinklein humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 AT louisebenning humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2 |
_version_ |
1721205486623129600 |
spelling |
doaj-e413afbaa85847fc89073dd1f5a18f3a2021-08-17T05:07:51ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.721286721286Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2Claudius Speer0Claudius Speer1Christian Morath2Maximilian Töllner3Mirabel Buylaert4Daniel Göth5Christian Nusshag6Florian Kälble7Matthias Schaier8Julia Grenz9Martin Kreysing10Paula Reichel11Asa Hidmark12Gerald Ponath13Paul Schnitzler14Martin Zeier15Caner Süsal16Katrin Klein17Louise Benning18Department of Nephrology, University of Heidelberg, Heidelberg, GermanyMolecular Medicine Partnership Unit Heidelberg, European Molecular Biology Laboratory (EMBL), Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Gastroenterology and Hepatology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyVirology, Department of Infectious Diseases, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanySeroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both P < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity.https://www.frontiersin.org/articles/10.3389/fmed.2021.721286/fullSARS-CoV-2COVID-19hemodialysisimmune responsevaccination |